Viewing Study NCT05903092


Ignite Creation Date: 2025-12-24 @ 3:45 PM
Ignite Modification Date: 2026-06-20 @ 4:40 PM
Study NCT ID: NCT05903092
Status: RECRUITING
Last Update Posted: 2025-05-04
First Post: 2023-06-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
Sponsor: Hirva Mamdani
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Small Cell Lung Cancer View
None SCLC View
None Extensive Stage Small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Small cell lung cancer View
None First-line therapy View
None Chemoimmunotherapy View
None Immunotherapy View
None Monalizumab View